Drug Profile
Research programme: anti-COVID-2019 monoclonal antibodies - Vanderbilt University Medical Center/National Resilience
Latest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Vanderbilt University Medical Center
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 27 Mar 2020 Twist Bioscience entered into collaboration agreement with Vanderbilt University Medical Center (VUMC) to supply synthetic genes and antibodies for the development of therapies for COVID-19
- 23 Mar 2020 Vanderbilt University Medical Center and Ology Bioservices agree to develop and manufacture monoclonal antibody for COVID-2019 infections
- 23 Mar 2020 Early research in COVID-2019 infections (Prevention) in USA (Parenteral)